Noemie S. Minczeles
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 27, 2022
Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men.
Journal: Clinical nuclear medicine
Published: April 15, 2022
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 13, 2022
Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients.
Journal: European journal of endocrinology
Published: January 11, 2022
Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 06, 2021
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 27, 2021
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Journal: Current oncology reports
Published: January 26, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026